SCHEDULE: Frazier Life Sciences Exits Adverum Biotech Stake

Frazier Life Sciences and related entities have reported a complete divestment of their beneficial ownership in Adverum Biotechnologies, Inc., now holding 0.0% of common stock.

Summary

• Frazier Life Sciences Public Fund, L.P. and its affiliated entities, including Frazier Life Sciences X, XI, and XII, along with individuals James N. Topper and Patrick J. Heron, no longer beneficially own any shares of Adverum Biotechnologies, Inc.
• The aggregate amount beneficially owned by each reporting person is 0.00 shares, representing 0.0% of the class of common stock.
• This filing is an Amendment No. 3 to a Schedule 13G, indicating a change from previous beneficial ownership reports.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment by a significant institutional investor like Frazier Life Sciences is generally a negative indicator for the company, suggesting a lack of confidence or a strategic shift away from the investment. While not directly impacting operations, it can influence market perception and share price negatively.

Negatives

• A significant institutional investor, Frazier Life Sciences, has fully divested its stake in Adverum Biotechnologies, Inc., reducing its beneficial ownership to 0.0%.
• The complete exit of a major investor could be perceived negatively by the market, potentially signaling a lack of confidence in the company's future prospects by that specific fund.

Risks

• The complete divestment by Frazier Life Sciences could lead to increased selling pressure on Adverum Biotechnologies' stock if other investors interpret this as a negative signal.
• A reduction in institutional ownership might decrease the stock's liquidity and investor interest.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Adverum Biotechnologies, Inc.'s future operations or financial performance.

Industry Context

The divestment by Frazier Life Sciences, a prominent life sciences investor, could reflect a strategic portfolio reallocation or a revised outlook on Adverum Biotechnologies' specific pipeline or market position within the competitive biotechnology sector. Such exits by specialized funds are closely watched by the market for potential implications on sector-specific investment trends.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential downward pressure on the stock price due to the exit of a major institutional investor.
• Potential Investors: May view the divestment as a red flag, potentially reducing interest in Adverum Biotechnologies' stock.

Key Dates

Recommendation

The complete divestment by Frazier Life Sciences, a prominent life sciences investor, signals a significant loss of institutional confidence in Adverum Biotechnologies. While the filing itself doesn't detail the reasons, such a full exit by a specialized fund often precedes or accompanies negative developments or a reassessment of the company's long-term prospects. This action could trigger further selling pressure and negative market sentiment, making a 'sell' recommendation prudent for investors seeking to mitigate potential downside risk.

Keywords

Adverum Biotechnologies, ADVM, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Biotechnology, SEC Filing